

Jennifer A Rothman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7938622/publications.pdf>

Version: 2024-02-01

53
papers

1,110
citations

516561

16
h-index

414303

32
g-index

54
all docs

54
docs citations

54
times ranked

1390
citing authors

#	ARTICLE	IF	CITATIONS
1	Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. <i>Lancet</i> , The, 2016, 387, 661-670.	6.3	375
2	Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. <i>Blood</i> , 2018, 131, 2183-2192.	0.6	121
3	Effects of hydroxyurea treatment for patients with hemoglobin <sc>SC</sc> disease. <i>American Journal of Hematology</i> , 2016, 91, 238-242.	2.0	54
4	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. <i>Haematologica</i> , 2019, 104, e51-e53.	1.7	46
5	Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. <i>Haematologica</i> , 2019, 104, 1974-1983.	1.7	43
6	Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. <i>Journal of Pediatric Surgery</i> , 2016, 51, 122-127.	0.8	39
7	Secondâ€line treatments in children with immune thrombocytopenia: Effect on platelet count and patientâ€centered outcomes. <i>American Journal of Hematology</i> , 2019, 94, 741-750.	2.0	37
8	Clinical outcomes of splenectomy in children: Report of the splenectomy in congenital hemolytic anemia registry. <i>American Journal of Hematology</i> , 2015, 90, 187-192.	2.0	33
9	The Spectrum of SPTA1-Associated Hereditary Spherocytosis. <i>Frontiers in Physiology</i> , 2019, 10, 815.	1.3	32
10	Physician decision making in selection of secondâ€line treatments in immune thrombocytopenia in children. <i>American Journal of Hematology</i> , 2018, 93, 882-888.	2.0	30
11	Further evidence for the involvement of <i>EFL1</i> in a Shwachmanâ€Diamond-like syndrome and expansion of the phenotypic features. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a003046.	0.5	29
12	Evaluation of partial and total splenectomy in children with sickle cell disease using an internetâ€based registry. <i>Pediatric Blood and Cancer</i> , 2012, 59, 100-104.	0.8	28
13	Executive functioning and health-related quality of life in pediatric sickle cell disease. <i>Child Neuropsychology</i> , 2017, 23, 889-906.	0.8	25
14	Aberrant splicing contributes to severe Î±-spectrinâ€linked congenital hemolytic anemia. <i>Journal of Clinical Investigation</i> , 2019, 129, 2878-2887.	3.9	24
15	Bleeding and thrombotic complications of pediatric liver transplant. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26955.	0.8	21
16	TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia. <i>Blood</i> , 2015, 126, 3-3.	0.6	19
17	The pyruvate kinase (PK) to hexokinase enzyme activity ratio and Åerythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. <i>British Journal of Haematology</i> , 2021, 192, 1092-1096.	1.2	15
18	Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 298-306.	1.0	14

#	ARTICLE	IF	CITATIONS
19	Diagnostic workâ€up for severe aplastic anemia in children: Consensus of the <sc>North American Pediatric Aplastic Anemia Consortium</sc>. American Journal of Hematology, 2021, 96, 1491-1504.	2.0	14
20	Trends in Sickle Cell Disease-related Priapism in U.S. Children's Hospitals. Urology, 2016, 89, 118-122.	0.5	10
21	Pyruvate kinase deficiency in children. Pediatric Blood and Cancer, 2021, 68, e29148.	0.8	10
22	Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis. Blood, 2020, 136, 18-19.	0.6	9
23	Characterization of the severe phenotype of pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, E281.	2.0	8
24	How I approach hereditary hemolytic anemia and splenectomy. Pediatric Blood and Cancer, 2020, 67, e28337.	0.8	8
25	Hydroxyurea Reduces Conversion From Conditional to Abnormal TCD Velocities In Children with Sickle Cell Anemia (SCA). Blood, 2010, 116, 270-270.	0.6	8
26	Clinical Characteristics and Quality of Life of Children with ITP Starting Second Line Treatments: Data from the ITP Consortium of North America ICON1 Study. Blood, 2016, 128, 249-249.	0.6	7
27	The clinical severity of hemoglobin S/Black (^AÎ²⁰)-thalassemia. Pediatric Blood and Cancer, 2017, 64, e26596.	0.8	5
28	Long-term hematologic and clinical outcomes of splenectomy in children with hereditary spherocytosis and sickle cell disease. Pediatric Blood and Cancer, 2020, 67, e28290.	0.8	5
29	Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants. Blood, 2015, 126, 3337-3337.	0.6	4
30	Variation in Serial TCD Velocity Measurements in the TCD with Transfusions Changing to Hydroxyurea (TWITCH) Trial. Blood, 2016, 128, 1019-1019.	0.6	4
31	Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice. Pediatric Blood and Cancer, 2011, 57, 1239-1243.	0.8	3
32	Systemic Loxoscelism in a Nonendemic Area. Clinical Pediatrics, 2014, 53, 1098-1100.	0.4	3
33	Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR). Blood Cells, Molecules, and Diseases, 2021, 87, 102534.	0.6	3
34	SARS-CoV-2 vaccination in pediatric patients with immune thrombocytopenia. Pediatric Blood and Cancer, 2022, 69, e29760.	0.8	3
35	Osteomyelitis in sickle cell disease: You know it when you see it?. Pediatric Blood and Cancer, 2020, 67, e28585.	0.8	2
36	Computerized cognitive training in pediatric sickle cell disease: A randomized controlled pilot study.. Clinical Practice in Pediatric Psychology, 2020, 8, 390-401.	0.2	2

#	ARTICLE	IF	CITATIONS
37	The Spectrum of Alpha-Spectrin Associated Hereditary Spherocytosis. Blood, 2015, 126, 941-941.	0.6	2
38	Health Related Quality of Life and Fatigue Improve on Second Line Treatments in Pediatric Immune Thrombocytopenia (ITP). Blood, 2017, 130, 752-752.	0.6	2
39	The Use of Chronic Transfusions in Sickle Cell Disease for Non-Stroke Related Indications. Blood, 2014, 124, 4934-4934.	0.6	1
40	The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status. Blood, 2015, 126, 2136-2136.	0.6	1
41	Postoperative Venous Thromboembolism in Children Is Increased in Setting of Cancer or Infection. Blood, 2016, 128, 2391-2391.	0.6	1
42	Iron Overload Is Highly Prevalent in All Disease Severity States in Pyruvate Kinase Deficiency (PKD). Blood, 2016, 128, 2430-2430.	0.6	1
43	Health Related Quality of Life and Fatigue in Patients with Pyruvate Kinase Deficiency. Blood, 2018, 132, 4807-4807.	0.6	1
44	Pyruvate Kinase (PK) Protein and Enzyme Levels in the Diagnosis and Clinical Phenotype of PK Deficiency. Blood, 2019, 134, 3515-3515.	0.6	1
45	Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained over Time in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat in a Long-Term Extension Study. Blood, 2021, 138, 848-848.	0.6	1
46	Complications of Implantable Venous Access Devices In Patients with Sickle Cell Disease. Blood, 2010, 116, 1649-1649.	0.6	0
47	Timing of the Initiation of Hydroxyurea and Hematologic Outcomes in Patients with Sickle Cell Disease (SCD). Blood, 2012, 120, 1004-1004.	0.6	0
48	Care of the Oncology Patient in the PICU. , 2014, , 343-361.		0
49	Physician Factors Determining Treatment Decisions in Selecting Second Line Agents for Pediatric ITP. Blood, 2016, 128, 1008-1008.	0.6	0
50	Comparison of Bleeding Tools in a Cohort of Pediatric Patients with ITP: Data from the Pediatric ITP Consortium of North America ICON1 Study. Blood, 2016, 128, 4752-4752.	0.6	0
51	Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency. Blood, 2019, 134, 949-949.	0.6	0
52	Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency. Blood, 2019, 134, 2175-2175.	0.6	0
53	A Retrospective Review of Hospital-Acquired Venous Thromboembolism at a Large Pediatric Tertiary Care Center. Blood, 2019, 134, 3471-3471.	0.6	0